Abstract P109: Lipid Accumulation Product (LAP) is Associated with Hepatic Steatosis Among Individuals without Metabolic Syndrome
Background: The Lipid accumulation product (LAP) is a simple index formulated to identify cardiometabolic disorders. It has been shown to be predictive of the metabolic syndrome (MS) and its associated risk. Hepatic steatosis (HS) is associated with cardiometabolic disorders and considered an independent risk factor for increased cardiovascular disease (CVD). We evaluated the association of LAP with HS is the presence and absence of MS in an asymptomatic population.
Methods: We evaluated 6,464 asymptomatic Brazilian subjects (43±10 years, 79% males) between November 2008 and July 2010. LAP (waist-58 х triglycerides [nmol/L]) was divided into quartiles and HS was defined by abdominal sonogram.
Results: The overall prevalence of HS was 36% (n=2,310). There was a steady increase in HS prevalence with LAP quartiles: Q1- 3%, Q2- 14%, Q3- 31%, Q4- 52, p<0.001. Twenty percent had MS, 75% of whom were in the 4th quartile of LAP. In a logistic regression analysis higher quartiles of LAP were independently associated with higher prevalent odds of HS. When stratified by the presence of MS, the association only remained significant among persons without MS. See Table below.
Conclusions: In an asymptomatic population there is an association between the higher LAP index and Hepatic Steatosis in persons without the metabolic syndrome. LAP index may be a relevant tool in predicting and screening for HS in individuals without MS.
Author Disclosures: E.T. Oni: None. O. Ogunmoroti: None. M. Blaha: None. A.S. Agatston: None. R.S. Blumenthal: None. J. Carvalho: None. R. Conceiçao: None. R.D. Santos: None. K. Nasir: None.
- © 2016 by American Heart Association, Inc.